Clinical trial
TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of…
NCT00023335 · Centers for Disease Control and Prevention, U.S. Fed · Completed
Key facts
| NCT number | NCT00023335 |
|---|---|
| Title | TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis |
| Official title | TBTC Study 22: Efficacy and Safety of Once-Weekly Rifapentine and Isoniazid Compared to Efficacy and Safety of Once-Weekly Rifapentine and Isoniazid Compared to Twice-Weekly Rifampin and Isoniazid in the Continuation Phase of Therapy for Pulmonary Tuberculosis |
| Lead sponsor | Centers for Disease Control and Prevention, U.S. Fed |
| Collaborators | US Department of Veterans Affairs U.S. Fed |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pulmonary Tuberculosis |
| Intervention type | Drug |
| Interventions | Rifapentine, Isoniazid |
| Enrollment | 1,000 |
| Start date | Apr 1, 1995 |
| Completion | Mar 1, 2001 |
| First posted | Sep 10, 2001 |
| Last update posted | Sep 5, 2005 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: